Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum + pediococcus acidilactici
- Development stage
- Preclinical
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum + pediococcus acidilactici is a probiotic combination therapy marketed under the brand name EQBIOTA (also known as AB-Intestin or i3.1). The formulation consists of three specific bacterial strains: *L. plantarum* CECT 7484, *L. plantarum* CECT 7485, and *P. acidilactici* CECT 7483. Developed by AB-Biotics, this live biotherapeutic product is primarily used to manage functional gastrointestinal disorders, including irritable bowel syndrome (IBS) and fructose malabsorption. Its mechanism of action involves the restoration of gut microbiota balance, enhancement of intestinal barrier integrity (reducing intestinal permeability), and modulation of local and systemic immune responses. Clinical studies have demonstrated its effectiveness in improving gastrointestinal symptoms such as bloating and abdominal pain by addressing underlying dysbiosis and gut barrier dysfunction.
- Brand names
- EQBIOTAAB-Intestini3.1i-3.1i 3.1
- Other names
- L. plantarum CECT 7484 + L. plantarum CECT 7485 + P. acidilactici CECT 7483
Beyond the preview
Go deeper on lactiplantibacillus plantarum + pediococcus acidilactici.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum + pediococcus acidilactici.